enGene Holdings Inc. Common Stock
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. enGen… Read more
enGene Holdings Inc. Common Stock (ENGN) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of January 2026: -0.103x
Based on the latest financial reports, enGene Holdings Inc. Common Stock (ENGN) has a cash flow conversion efficiency ratio of -0.103x as of January 2026.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-28.90 Million) by net assets ($281.55 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
enGene Holdings Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how enGene Holdings Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
enGene Holdings Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of enGene Holdings Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MCBC Holdings Inc
NASDAQ:MCFT
|
0.082x |
|
Motech Industries Co Ltd
TWO:6244
|
0.132x |
|
Jiangxi Haiyuan Composites Technology Co Ltd
SHE:002529
|
0.167x |
|
Knowit AB
LSE:0GNK
|
0.078x |
|
Ventive Hospitality Ltd
NSE:VENTIVE
|
0.021x |
|
Zhejiang Busen Garments Co Ltd
SHE:002569
|
-0.793x |
|
Groenlandsbanken AS
CO:GRLA
|
0.003x |
|
Microvision Inc
NASDAQ:MVIS
|
-0.277x |
Annual Cash Flow Conversion Efficiency for enGene Holdings Inc. Common Stock (2021–2025)
The table below shows the annual cash flow conversion efficiency of enGene Holdings Inc. Common Stock from 2021 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-10-31 | $167.71 Million | $-99.24 Million | -0.592x | -234.11% |
| 2024-10-31 | $272.61 Million | $-48.28 Million | -0.177x | +48.12% |
| 2023-10-31 | $72.49 Million | $-24.74 Million | -0.341x | -147.25% |
| 2022-10-31 | $127.42 Million | $-17.59 Million | -0.138x | -10.03% |
| 2021-10-31 | $127.39 Million | $-15.98 Million | -0.125x | -- |